HomepageCRSP • NASDAQ
add
Crispr Therapeutics AG
$Â 45,55
Na sluitingstijd:(1,87%)+0,85
$Â 46,40
Gesloten: 23 jun, 19:59:03 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 44,25
Dag-range
$Â 43,23 - $Â 45,79
Jaar-range
$Â 30,06 - $Â 63,68
Beurswaarde
3,93Â mld. USD
Gem. volume
2,37Â mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 865,00K | 71,63% |
Bedrijfskosten | 19,30Â mln. | 7,48% |
Netto inkomsten | -136,00Â mln. | -16,64% |
Netto winstmarge | -15,72K | 32,04% |
Winst per aandeel | -1,58 | -10,49% |
EBITDA | -143,69Â mln. | -5,84% |
Effectief belastingtarief | -0,82% | — |
Balans
Totale activa
Totale passiva
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 1,86Â mld. | -11,99% |
Totale activa | 2,17Â mld. | -11,19% |
Totale passiva | 336,94Â mln. | -5,11% |
Totaal aandelenvermogen | 1,83 mld. | — |
Uitstaande aandelen | 86,36 mln. | — |
Koers-boekwaardeverhouding | 2,09 | — |
Rendement op activa | -16,84% | — |
Rendement op kapitaal | -17,65% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -136,00Â mln. | -16,64% |
Operationele kasstroom | -53,95Â mln. | -149,15% |
Kasstroom uit beleggingen | -19,76Â mln. | 79,80% |
Kasstroom uit financiering | 10,59Â mln. | -96,54% |
Nettomutatie in liquide middelen | -63,07Â mln. | -119,84% |
Vrije kasstroom | -15,60Â mln. | -110,51% |
Over
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Opgericht
2013
Hoofdvestiging
Website
Werknemers
393
